|
Bapineuzumab
Today Elan Pharmaceuticals and Wyeth announced that they will begin phase III clinical trials on Bapineuzumab for Alzheimers disease based on the data seen at midpoint PII trials. The data seen has not been released and will not be until PII is concluded but this is almost 6 months before the PII trial is over!!
Whatever they saw MUST be GOOD!!! |
| All times are GMT -5. The time now is 03:12 PM. |
Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.